These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 10357952)

  • 101. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization.
    Maroulis GB; Emery M; Verkauf BS; Saphier A; Bernhisel M; Yeko TR
    Fertil Steril; 1991 Jun; 55(6):1157-64. PubMed ID: 1903732
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?
    Engel JB; Ludwig M; Felberbaum R; Albano C; Devroey P; Diedrich K
    Hum Reprod; 2002 Aug; 17(8):2022-6. PubMed ID: 12151431
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Plasmatic estradiol concentration in the mid-luteal phase is a good prognostic factor for clinical and ongoing pregnancies, during stimulated cycles of in vitro fertilization.
    Florêncio RS; Meira MSB; Cunha MVD; Camarço MNCR; Castro EC; Finotti MCCF; Oliveira VA
    JBRA Assist Reprod; 2018 Mar; 22(1):8-14. PubMed ID: 29338136
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Results of gonadotrophin stimulation with the option to convert cycles to in vitro fertilization in cases of multifollicular development.
    Bergh C; Bryman I; Nilsson L; Janson PO
    Acta Obstet Gynecol Scand; 1998 Jan; 77(1):68-73. PubMed ID: 9492722
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial.
    Akman MA; Erden HF; Tosun SB; Bayazit N; Aksoy E; Bahceci M
    Hum Reprod; 2001 May; 16(5):868-70. PubMed ID: 11331630
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Impact of estradiol patterns in clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol.
    Lin YH; Seow KM; Chen HJ; Huang LW; Hwang JL; Tzeng CR
    Gynecol Endocrinol; 2007 Jan; 23(1):45-9. PubMed ID: 17484512
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix.
    Boerrigter PJ; de Bie JJ; Mannaerts BM; van Leeuwen BP; Passier-Timmermans DP
    Hum Reprod; 2002 Aug; 17(8):2027-34. PubMed ID: 12151432
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor.
    Mannaerts B; Gordon K
    Hum Reprod; 2000 Sep; 15(9):1882-3. PubMed ID: 10966979
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/in-vitro fertilization prior to cancer treatment.
    Anderson RA; Kinniburgh D; Baird DT
    Hum Reprod; 1999 Oct; 14(10):2665-8. PubMed ID: 10528005
    [TBL] [Abstract][Full Text] [Related]  

  • 110. The effect of gonadotrophin-releasing hormone agonist versus human chorionic gonadotrophin trigger on pregnancy and neonatal outcomes in Letrozole-HMG IUI cycles.
    Chen L; Xi Q; Jiang S; Gao Y; Long H; Wang Y; Kuang Y
    BMC Pregnancy Childbirth; 2023 Jul; 23(1):512. PubMed ID: 37442967
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Use of gonadotrophin releasing hormone (GnRH) antagonist (cetrotide) during ovarian stimulation for in-vitro fertilization treatment: multiple doses and single dose.
    Ng EH; Ho PC
    J Obstet Gynaecol Res; 2001 Oct; 27(5):261-5. PubMed ID: 11776508
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Luteal phase consequences of low-dose gonadotropin-releasing hormone agonist therapy in nonluteal-supported in vitro fertilization cycles.
    Long CA; Sopelak VM; Lincoln SR; Cowan BD
    Fertil Steril; 1995 Sep; 64(3):573-6. PubMed ID: 7641913
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Embryo transfer and luteal support in natural cycles.
    Vlaisavljevic V
    Reprod Biomed Online; 2007 Jun; 14(6):686-92. PubMed ID: 17579979
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Evaluation of growth hormone co-treatment in in vitro fertilization in patients responding better to the GnRH antagonist short protocol.
    Macedo JF; Oliveira MR; Gomes LMO; Macedo GC; Macedo GC; Gomes DO; Martins OG; Ambrogi BO; Santos SISD
    JBRA Assist Reprod; 2020 May; 24(2):147-151. PubMed ID: 32155012
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Mid-luteal endometrial intracrinology following controlled ovarian hyperstimulation involving use of a gonadotrophin releasing hormone antagonist.
    Vani S; McDonald SE; Williams AR; Mason JI; Thong KJ; Critchley HO
    Hum Reprod; 2007 Nov; 22(11):2981-91. PubMed ID: 17848403
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Enhanced oestradiol secretion briefly after embryo transfer in conception cycles from IVF.
    Greb RR; Lettmann N; Sonntag B; Schüring AN; von Otte S; Kiesel L
    Reprod Biomed Online; 2004 Sep; 9(3):271-8. PubMed ID: 15353074
    [TBL] [Abstract][Full Text] [Related]  

  • 117. The luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotropin with and without leuprolide acetate.
    Bachus KE; Hughes CL; Haney AF; Dodson WC
    Fertil Steril; 1990 Jul; 54(1):27-31. PubMed ID: 2113488
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Impact of ovarian stimulation on corpus luteum function and embryonic implantation.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    J Reprod Immunol; 2002; 55(1-2):123-30. PubMed ID: 12062827
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome.
    Sharara FI; McClamrock HD
    Hum Reprod; 1999 Nov; 14(11):2777-82. PubMed ID: 10548621
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Repeated application of luteal phase oestradiol/GnRH antagonist priming increases IVF success for poor ovarian reserve patients.
    Ceyhan T; Ozturk M; Yıldız UG; Fidan U; Agacayak E; Ulubay M; Korkmaz C
    J Obstet Gynaecol; 2023 Dec; 43(2):2211664. PubMed ID: 37289635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.